A real‑life analysis on the indications and prognostic relevance of perioperative chemotherapy in locally advanced resectable gastric adenocarcinoma

• F. Pardo ^[1] ; J. Osorio ^[7] ; C. Miranda ^[8] ; S. Castro ^[2] ; M. Miró ^[3] ; A. Luna ^[4] ; E. Garsot ^[1] ; D. Momblán ^[5] ; G. Galofré ^[6] ; J. Rodríguez Santiago ^[7] ; M. Pera ^[9]
  1. [1] Hospital Universitari Germans Trias i Pujol

     Hospital Universitari Germans Trias i Pujol

     Barcelona, España

     
  2. [2] Universitat Autònoma de Barcelona

     Universitat Autònoma de Barcelona

     Barcelona, España

     
  3. [3] Hospital Universitari de Bellvitge

     Hospital Universitari de Bellvitge

     l'Hospitalet de Llobregat, España

     
  4. [4] Corporació Sanitària Parc Taulí

     Corporació Sanitària Parc Taulí

     Barcelona, España

     
  5. [5] Universitat de Barcelona

     Universitat de Barcelona

     Barcelona, España

     
  6. [6] Hospital de Sant Joan Despí Moisès Broggi

     Hospital de Sant Joan Despí Moisès Broggi

     Barcelona, España

     
  7. [7] Service of General and Digestive Surgery, Hospital Universitari Mútua de Terrassa, Terrassa, Barcelona, Spain
  8. [8] Esophagogastric Surgery Unit, Complejo Hospitalario de Navarra, Pamplona, Spain
  9. [9] Section of Gatrointestinal Surgery, Hospital Universitari del Mar, IMIM (Hospital del Mar Medical Research Institute), Universitat Autònoma de Barcelona, Barcelona, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 8, 2020, págs. 1335-1344
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background and purpose Perioperative chemotherapy (periCTX) based on the “MAGIC” scheme has become a standard treatment in Europe for locally advanced oesophagogastric cancer. We assessed implementation and long-term oncological outcomes of MAGIC periCTX for locally advanced gastric cancer.

    Methods Population-based cohort study of all patients with locally advanced gastric cancer undergoing surgical resection with curative intent in Catalonia and Navarra (the first two autonomous communities included in the EURECCA Upper GI Spanish Working Group) between January 2011 and December 2013. The main variable was the percentage of patients treated with MAGIC periCTX. Kaplan–Meier analysis and Cox proportional hazards model were used to assess the survival benefit of periCTX.

    Results Among 814 patients, 217 (26.6%) received periCTX (especially patients more likely to receive it: aged < 70 years, with proximal tumors, low anesthetic risk, and cT3–4/cN+ clinical stage). 35% did not complete perioperative chemotherapy, with no relationship with age. PeriCTX showed no effect on postoperative morbimortality. Histological tumor regression was more often absent or poor (38.2%) than total or almost total (27.8%), although clinico-pathological lymph-node downstaging was higher than expected by staging inaccuracy (38.7% vs. 24.2%). PeriCTX was associated with a better survival only in cT3–4 and cN+ patients, showing less prognostic relevance than optimal oncological surgery with D2 lymphadenectomy.

    Conclusions Only 26.6% of locally advanced resectable gastric cancer patients received PeriCTX. Pathological response was poor, although some degree of nodal downstaging was observed. Survival benefit of periCTX was limited to cT3–4 and cN+ patients, being less relevant than D2 lymphadenectomy.